What you clearly fail to appreciate is that with the advent of molecular targeted therapies, the treatment of cancer is undergoing a dramatic shift not seen since the advent of chemotherapy around 60 years ago.
The ability to identify the genetic and molecular signature of tumor cells has given companies like Ariad the ability to design drugs that specifically target the defective molecular pathways responsible for the cancer cell's abnormal properties. Take ALK for example, it's either present in adults or its not. And if it is present, then either AP113 is able to target it or its not. There's no guesswork here. It's no longer a question of whether a drug works or not its a question of how well it works and how safe it is. The same thing is true with AP534 - either the T315I mutation is present or its not and if it is we know that AP534 is able to target it very, very well.
Like many of your arguments, I find your characterization of this as vapor-ware to be far too simplistic.
